ArticleCancer medicine2015

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.

Luis-Felipe Casado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.